We are live on ! Find out more
DSCI

Derma Sciences, Inc. Common Stock (DE)
DSCI

Delisted

DSCI was delisted on the 23rd of February, 2017.

63 hedge funds and large institutions have $193M invested in Derma Sciences, Inc. Common Stock (DE) in 2014 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 19

13% more capital invested

Capital invested by funds: $171M → $193M (+$22M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

10% less funds holding

Funds holding: 7063 (-7)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $534K

Holders
63
Holders Change
-7
Holders Change %
-10%
% of All Funds
1.68%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
4
Increased
25
Reduced
19
Closed
9
Calls
Puts
$534K
Net Calls
-$534K
Net Calls Change
+$278K
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$32.9M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$18.2M -$224K -25,800 -1%
BC
3
Broadfin Capital
New York
$17.3M +$283K +32,500 +2%
CCM
4
Consonance Capital Management
New York
$15.2M +$976K +112,223 +7%
GPP
5
Great Point Partners
Connecticut
$11M +$209K +24,028 +2%
SM
6
Senvest Management
New York
$10.7M +$3.05M +350,481 +44%
Jennison Associates
7
Jennison Associates
New York
$10.6M -$110K -12,648 -1%
HM
8
HealthCor Management
New York
$8.56M
JP Morgan Chase
9
JP Morgan Chase
New York
$7.21M -$2.36M -271,230 -26%
DM
10
Deerfield Management
New York
$6.72M +$1.46M +167,489 +30%
BFA
11
BlackRock Fund Advisors
California
$5.75M +$734K +84,448 +16%
Vanguard Group
12
Vanguard Group
Pennsylvania
$5.06M +$127K +14,644 +3%
DCM
13
DAFNA Capital Management
California
$3.58M
JGC
14
J. Goldman & Co
New York
$3.4M +$3.17M +365,000 New
GIM
15
Granahan Investment Management
Massachusetts
$3.06M -$255K -29,377 -8%
PA
16
Perceptive Advisors
New York
$2.92M +$850K +97,774 +45%
O
17
OrbiMed
New York
$2.79M
RAM
18
Roanoke Asset Management
New Jersey
$2.48M +$954K +109,685 +70%
State Street
19
State Street
Massachusetts
$2.35M +$64.2K +7,380 +3%
UBS AM
20
UBS AM
Illinois
$2.32M -$1.04M -119,146 -32%
Northern Trust
21
Northern Trust
Illinois
$2.24M -$114K -13,096 -5%
Adage Capital Partners
22
Adage Capital Partners
Massachusetts
$2.18M +$1.39M +159,442 +213%
BIT
23
BlackRock Institutional Trust
California
$2.1M -$47.1K -5,416 -2%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$1.67M +$42K +4,834 +3%
Fidelity International
25
Fidelity International
Bermuda
$1.58M

DSCI Hedge Fund Activity: Q4 2014 in Review

63 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Derma Sciences, Inc. Common Stock (DE) (DSCI) for Q4 2014, worth a combined $193M — up 13% from $171M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of DSCI and 4 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 25 added.

The largest buyer was Teachers Advisors, adding an estimated $30.4M. The largest seller was THB Asset Management, exiting entirely with an estimated $5.29M sold.

  • 63 institutional investors held Derma Sciences, Inc. Common Stock (DE) (DSCI) as of Q4 2014, down from 70 in Q3 2014.
  • Funds reported $193M of Derma Sciences, Inc. Common Stock (DE) stock for Q4 2014, up 13% quarter-over-quarter.
  • 4 funds opened new Derma Sciences, Inc. Common Stock (DE) positions in Q4 2014 and 9 closed out, a net change of -5 holders.
  • The largest Derma Sciences, Inc. Common Stock (DE) buyer in Q4 2014 was Teachers Advisors, an estimated $30.4M added.
  • The largest Derma Sciences, Inc. Common Stock (DE) seller in Q4 2014 was THB Asset Management, an estimated $5.29M sold.

Based on aggregated 13F filings for Q4 2014.